In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Related to this article
Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.
Advertisement
Advertisement
Trending on OncLive
1
Dr Skoulidis on First-Line Divarasib Plus Pembrolizumab in KRAS G12C+ NSCLC
2
Dr Cortés on Developing CD47 as a Biomarker in Pretreated HER2+ Breast Cancer
3
Dr Oberstein on the Design of Autogene Cevumeran in PDAC
4
Dr Morillo on Efficacy Data for Golcadomide in R/R Follicular Lymphoma
5